Sentinel lymph node biopsy in early stage ovarian cancer: A prospective observational study

  • 0Department of Obstetrics and Gynaecology (Gynaecologic Oncology), All India Institute of Medical Sciences, Rishikesh, India.

Summary

This summary is machine-generated.

Sentinel lymph node biopsy (SLNB) accurately assesses lymph node status in early-stage epithelial ovarian cancer. This technique, using radioactive tracers and blue dye, avoids extensive surgery and identifies isolated tumor cells.

Area Of Science

  • Oncology
  • Surgical Pathology

Background

  • Sentinel lymph node biopsy (SLNB) is crucial for staging various cancers, minimizing morbidity by avoiding complete lymphadenectomy.
  • Its role in epithelial ovarian cancer (EOC) requires further evaluation to optimize patient management.

Purpose Of The Study

  • To assess the feasibility and accuracy of SLNB in patients with suspected early-stage epithelial ovarian cancer.
  • To evaluate the combined use of a radioactive tracer and blue dye for sentinel lymph node identification.

Main Methods

  • A prospective observational study involving 29 patients with suspected stage I/II EOC.
  • Subperitoneal injection of tracers followed by SLN identification and systematic lymphadenectomy.
  • SLNs were subjected to ultrastaging for precise pathological assessment.

Main Results

  • A 100% SLN detection rate was achieved using the combination of radioactive tracer and blue dye.
  • The SLNB demonstrated 100% sensitivity, specificity, and predictive values when a sentinel node was detected.
  • Ultrastaging identified isolated tumor cells (ITCs) in five cases, with no observed complications.

Conclusions

  • SLNB is a feasible and accurate method for lymph node staging in epithelial ovarian cancer.
  • The combination of tracers enhances detection rates, offering a less invasive staging option.
  • While ultrastaging detects ITCs, their clinical significance in EOC warrants further investigation.